Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Peter Benenson (born Peter James Henry Solomon; 31 July 1921 – 25 February 2005) British lawyer, writer, pamphleteer, human rights activist and the founder of human rights group Amnesty International (AI); accepted the Pride of Britain Award for Lifetime Achievement in 2001 though he later rejected and denounced Amnesty International for its criticism of Israel. Benenson was the son of British-born Harold Solomon and Russian-born Flora Benenson, grandson of Russian financier Grigori Benenson (1860–1939); served in Intelligence Corps at the Ministry of Information and worked at Bletchley Park during World War II as a cryptographer. Leila Berg (12 November 1917 – 17 April 2012) was an English children's author, editor and play specialist. She was well known as a journalist and a writer on education and children's rights. Berg was a recipient of the Eleanor Farjeon Award. John Berger, Jewish father, convert to Roman Catholicism, (5 November 1926 – 2 January 2017) English art critic, novelist, painter and poet. Berger's essay on art criticism Ways of Seeing, is known as a foundation text employing deconstruction and feminist prisms of epistemology and ontology, questioning axiomatic assumptions about gender, racial prejudice and Orientalism, whilst introducing and debating prisms of Psychological projection, Reification (Marxism), False Consciousness, Commodity fetishism, Marx's theory of alienation and essentialism. He was a supporter of the Palestinian cause, and, focused on Israel and apartheid, a member of the Support Committee of the Russell Tribunal on Palestine.
Such a view is in contradiction of the "Open Design" principle of the National Institute of Standards and Technology's Guide to General Server Security which states that "system security should not depend on the secrecy of the implementation or its components", which can be considered as a reiteration of Kerckhoffs's principle.
In the US, esketamine (brand name Spravato) is a nasal spray indicated, as monotherapy, or in conjunction with an oral antidepressant as a therapy for treatment-resistant depression (TRD) as well as major depressive disorder (MDD) associated with suicidal ideation or behavior in adults. In the clinical trials that led to approval of esketamine, TRD was defined as major depressive disorder with inadequate response to at least two different conventional antidepressants. The nasal spray formulation of esketamine used for depression delivers two sprays containing a total of 28 mg esketamine and doses of 56 mg (2 devices) to 84 mg (3 devices) are used. Esketamine has modest short-term efficacy on TRD (similar in efficacy to atypical antipsychotics); there is limited long-term safety data available and some concerning signals regarding adverse events and abuse potential. Due to concerns about sedation, dissociation, and misuse, esketamine is available for treatment of depression only from certified providers through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Spravato REMS.
In addition to these biomarkers, the FDA has approved certain drug-companion diagnostic pairings based on genetic mutations. For example, BRAF-targeted therapies for metastatic melanoma are only indicated for patients whose tumors harbor a BRAF mutation. While these tests are now commonly marketed as essential tools for precision oncology, they remain costly. Moreover, some have been the subject of controversy or misuse. Notable examples include the Duke University cancer fraud scandal and questionable claims surrounding so-called "liquid biopsies."
Sources: en.wikipedia.org
The creation of British Nationality (Overseas) status, for instance, (with fewer privileges than British citizen status) was met with criticism from many Hong Kong residents who felt that British citizenship would have been more appropriate in light of the "moral debt" owed to them by the UK. Some British politicians and magazines also criticised the creation of BN(O) status. In 2020, the British government under Boris Johnson announced a program under which BN(O)s would have leave to remain in the UK with rights to work and study for five years, after which they may apply for settled status. They would then be eligible for full citizenship after holding settled status for 12 months. This was implemented as the eponymously named "British National (Overseas) visa", a residence permit that BN(O)s and their dependent family members have been able to apply for since 31 January 2021. BN(O)s and their dependents who arrived in the UK before the new immigration route became available were granted "Leave Outside the Rules" at the discretion of the Border Force to remain in the country for up to six months as a temporary measure. In effect, this retroactively granted BN(O)s a path to right of abode in the United Kingdom. Despite the COVID-19 pandemic, about 7,000 people had entered the UK under this scheme between July 2020 and January 2021.
== Overview == The idea of using DNA as a construction material was first introduced in the early 1980s by Nadrian Seeman. The method of DNA origami was developed by Paul Rothemund at the California Institute of Technology. In contrast to common top-down fabrication methods such as 3D printing or lithography which involve depositing or removing material through a tool, DNA Nanotechnology, as well as DNA origami as a subset, is a bottom-up fabrication method. By rationally designing the constituent subunits of the DNA polymer, DNA can self-assemble into a variety of shapes. The process of constructing DNA origami involves the folding of a long single strand of viral DNA (typically the 7,249 bp genomic DNA of M13 bacteriophage) aided by multiple smaller "staple" strands. These shorter strands bind the longer in various places, resulting in the formation of a pre-defined two- or three-dimensional shape. Examples include a smiley face and a coarse map of China and the Americas, along with many three-dimensional structures such as cubes. There are several DNA properties that make the molecule an ideal building material for DNA origami. DNA strands have a natural tendency to bind to their complementary sequences through Watson–Crick base pairing. This allows staple strands to locate the position on the scaffold strand without any external manipulation, leading to self-assembly of the desired structure. The specific sequence of bases in DNA gives the material an element of programmability by determining its binding behavior.
== Career in industry == Between the year 1947 and 1969, Beynon was Manager of Physics and Physical, Polymer and Analytical Chemistry at Imperial Chemical Industries. Between 1947 and 1950, Beynon constructed what was to become the first mass spectrometer designed to study organic compounds unrelated to petroleum. He subsequently collaborated with Metropolitan-Vickers to produce the MS8 mass spectrometer, a prototype of the Associated Electrical Industries (AEI) MS9 mass spectrometer. Beynon was made a senior research associate in 1964 which allowed him the opportunity to carry out his own research. He was a Boomer Memorial Fellow at the University of Minnesota in 1965.
Sources: en.wikipedia.org
The reign of Juan Carlos I as king of Spain began on November 22, 1975, with his accession to the throne following the death of dictator Francisco Franco, who had designated him as successor and Prince of Spain in 1969, and ended on June 19, 2014, with his abdication.
Galectin-7 is a protein that in humans is encoded by the LGALS7 gene. The galectins are a family of beta-galactoside-binding lectins involved in modulating cell–cell and cell–matrix interactions. LGALS7 is specifically expressed in keratinocytes and at all stages of epidermal differentiation, including the basal and suprabasal layers. Expression is moderately repressed by retinoic acid. In tissue sections, galectin-7 localizes primarily to basal keratinocytes but is also found, at lower levels, in suprabasal layers where it concentrates at sites of cell–cell contact. Its down-regulation in cultured keratinocytes suggests a role in adhesion-related growth control. Galectin-7, like other galectins, binds carbohydrate structures containing galactose. Galactosides contribute to glycoprotein architecture and to processes such as oligosaccharide hydrolysis, and the structural diversity of these sugars underlies the selective affinity of galectins for their glycan ligands. Consistent with its keratinocyte-specific expression, galectin-7 is abundant in the epidermis and other stratified epithelia. The LGALS7 gene participates in fundamental cellular processes such as apoptosis and cell–cell interactions. Galectin-7 contributes to epithelial maintenance, wound repair, and cellular stress responses, and shows context-dependent roles in immunity, infection, and cancer. Its carbohydrate-binding specificity gives rise to distinct signaling outputs, making therapeutic targeting challenging.
He sent Signoret specimens of American grape lice, which Signoret concluded – in 1870, while he was besieged in Paris during the Franco-Prussian War – were indeed identical to French grape lice. Meanwhile, Planchon and Lichtenstein had found vines with afflicted leaves; lice that were transferred from those leaves to the roots of healthy vines attached themselves to the vines' roots as other French grape lice did. Also in 1870, Riley discovered that American grape lice wintered on American grape vines' roots, which the insects damaged, albeit less than in the case of French vines. Riley repeated Planchon and Lichtenstein's experiment using American grape vines and American grape lice, with similar results. Thus the identity of the French and American grape lice was proven. Nevertheless, for another three years, a powerful majority in France argued that Phylloxera was not the cause of vine disease; instead, vines that were already sickly became infested with Phylloxera. Thus, in their opinion, Phylloxera was merely a consequence of the "true" disease, which remained to be found. Regardless, Riley had discovered American grape varieties that were especially resistant to Phylloxera, and by 1871, French farmers began to import them and to graft French vines onto the American rootstock. (Leo Laliman had suggested importing American vines as early as 1869, but French farmers were reluctant to abandon their traditional varieties.
Research carried out by Kantar indicates that September's warm weather delayed the purchase of Christmas food items such as seasonal biscuits and puddings. The International Monetary Fund forecasts the UK will have the highest inflation and slowest economic growth of any G7 economy during 2024, something the UK government describes as "too gloomy". All flights from Luton Airport are halted while emergency services deal with a large fire at Terminal Car Park 2. 11 October An official source tells BBC News that 17 Britons, including children, are feared dead or are missing in Israel following the Hamas attacks. A statement issued by Buckingham Palace says that King Charles III is "appalled" and condemns the "barbaric acts of terrorism in Israel" and that the King's "thoughts and prayers are with all of those suffering, particularly those who have lost loved ones, but also those actively involved as we speak". British Airways and Virgin Atlantic suspend all flights to and from Israel amid safety concerns, with British Airways turning back one of its flights shortly before it was scheduled to land at Tel Aviv Airport. 12 October Data from the Office for National Statistics indicates the UK economy grew by 0.2% in August after shrinking in July. Bernie Ecclestone pleads guilty to fraud after failing to declare more than £400m of overseas assets. The SNP's Lisa Cameron defects to the Conservatives, citing a "toxic" culture in her former party. The Foreign Office announces that the UK will arrange flights to help get stranded British nationals out of Israel.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.